Wall Street analysts expect that Atreca (NASDAQ:BCEL) will announce ($0.66) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Atreca’s earnings. The company is scheduled to issue its next quarterly earnings report on Tuesday, February 18th.
On average, analysts expect that Atreca will report full-year earnings of ($3.36) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will report earnings of ($3.14) per share. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Atreca.
Atreca (NASDAQ:BCEL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.09.
A number of research firms have recently weighed in on BCEL. Zacks Investment Research downgraded shares of Atreca from a “buy” rating to a “hold” rating in a research report on Tuesday, February 4th. BidaskClub raised shares of Atreca from a “hold” rating to a “buy” rating in a research note on Wednesday, February 5th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $23.73.
NASDAQ BCEL opened at $20.33 on Friday. Atreca has a 1-year low of $9.51 and a 1-year high of $23.65. The company has a 50 day moving average of $17.03 and a 200-day moving average of $14.10.
In related news, insider Guy Cavet sold 10,000 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the sale, the insider now owns 92,758 shares of the company’s stock, valued at $1,855,160. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Norman Michael Greenberg sold 15,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $19.65, for a total transaction of $294,750.00. Following the completion of the sale, the insider now directly owns 15,000 shares in the company, valued at approximately $294,750. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,919 shares of company stock worth $690,193.
Institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Atreca in the second quarter valued at $17,721,000. Vanguard Group Inc. acquired a new position in Atreca in the second quarter valued at $2,769,000. Morgan Stanley acquired a new position in Atreca in the second quarter valued at $43,000. Cubist Systematic Strategies LLC acquired a new position in Atreca in the second quarter valued at $106,000. Finally, State Street Corp acquired a new position in Atreca in the third quarter valued at $1,056,000. 57.72% of the stock is currently owned by institutional investors.
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Read More: What are the benefits of a portfolio tracker?
Get a free copy of the Zacks research report on Atreca (BCEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.